| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46417 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5840279 | COVIS | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
Jun, 2016
(7 years ago) | |
| US6071498 | COVIS | Inhaler for powdered medicaments |
Jun, 2016
(7 years ago) | |
| US9333195 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US10034867 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US9056100 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US10588895 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US7078412 | COVIS | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(3 years ago) | |
| US6750226 | COVIS | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Sep, 2020
(3 years ago) | |
| US6681768 | COVIS | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(1 year, 8 months ago) | |
| US8051851 | COVIS | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(2 years from now) | |
| US10085974 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
| US11000517 | COVIS | Dosage and formulation |
Mar, 2029
(4 years from now) | |
Tudorza Pressair is owned by Covis.
Tudorza Pressair contains Aclidinium Bromide.
Tudorza Pressair has a total of 13 drug patents out of which 9 drug patents have expired.
Expired drug patents of Tudorza Pressair are:
- US5840279
- US6071498
- US9333195
- US10034867
- US9056100
- US10588895
- US7078412
- US6750226
- US6681768
Tudorza Pressair was authorised for market use on 23 July, 2012.
Tudorza Pressair is available in powder, metered;inhalation dosage forms.
Tudorza Pressair can be used as maintenance treatment of chronic obstructive pulmonary disease (copd), maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), treatment of chronic obstructive pulmonary disease (copd) or chronic bronchitis, maintenance treatment of chronic pulmonary disease (copd), treatment of a respiratory disease.
Drug patent challenges can be filed against Tudorza Pressair from 23 July, 2016.
The generics of Tudorza Pressair are possible to be released after 13 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-256) | Mar 29, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2017 |
Drugs and Companies using ACLIDINIUM BROMIDE ingredient
NCE-1 date: 23 July, 2016
Market Authorisation Date: 23 July, 2012
Treatment: Maintenance treatment of chronic obstructive pulmonary disease (copd); Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd); Maintenance treatment of chro...
Dosage: POWDER, METERED;INHALATION
TUDORZA PRESSAIR family patents
